| Authors: |
Classen AY; Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, University of Cologne, Cologne, Germany; German Centre for Infection Research (DZIF), Braunschweig, Germany; Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; ESGNTA - ESCMID Study Group for Nontraditional Antibacterials, Basel, Switzerland. Electronic address: annika.classen@uk-koeln.de., Clokie MRJ; Becky Meyer Centre for Phage Research, Division of Microbiology and Infection, School of Biological and Biomedical Sciences, University of Leicester, Leicester, UK., Giske CG; ESGNTA - ESCMID Study Group for Nontraditional Antibacterials, Basel, Switzerland; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden., Paz RN; ESGNTA - ESCMID Study Group for Nontraditional Antibacterials, Basel, Switzerland; Hadassah-Hebrew University Medical Center, and The Faculty of Medicine, the Hebrew University, Jerusalem, Israel., Pirnay JP; ESGNTA - ESCMID Study Group for Nontraditional Antibacterials, Basel, Switzerland; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium., Resch G; ESGNTA - ESCMID Study Group for Nontraditional Antibacterials, Basel, Switzerland; Laboratory of Bacteriophages and Phage Therapy, Center for Research and Innovation in Clinical Pharmaceutical Science (CRISP), Lausanne University Hospital (CHUV), Lausanne, Switzerland., Laurent F; ESGNTA - ESCMID Study Group for Nontraditional Antibacterials, Basel, Switzerland; Therapeutic Phage Laboratory, Institute for Infectious Agents, Hospices Civils de Lyon, Lyon, France; Team 'Staphylococcal pathogenesis', Centre International de Recherche en Infectiologie (CIRI), INSERM U1111 - CNRS UMR5308 - ENS Lyon - Lyon 1 University, Code 2025, Lyon, France. |
